3/10
11:11 am
akro
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its "overweight" rating re-affirmed by analysts at Morgan Stanley.
Low
Report
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its "overweight" rating re-affirmed by analysts at Morgan Stanley.
3/10
11:11 am
akro
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its "overweight" rating re-affirmed by analysts at Morgan Stanley.
Low
Report
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its "overweight" rating re-affirmed by analysts at Morgan Stanley.
2/3
07:57 pm
akro
89bio initiated with an Outperform at Wolfe Research
Medium
Report
89bio initiated with an Outperform at Wolfe Research
2/3
07:57 pm
akro
89bio initiated with an Outperform at Wolfe Research
Medium
Report
89bio initiated with an Outperform at Wolfe Research
1/31
02:02 pm
akro
Rating for AKRO
Low
Report
Rating for AKRO
1/28
12:17 pm
akro
Rating for AKRO
Medium
Report
Rating for AKRO
1/28
12:17 pm
akro
Rating for AKRO
Medium
Report
Rating for AKRO
1/28
07:08 am
akro
Rating for AKRO
Low
Report
Rating for AKRO
1/28
07:08 am
akro
Rating for AKRO
Low
Report
Rating for AKRO
1/28
06:38 am
akro
Rating for AKRO
Low
Report
Rating for AKRO
1/16
11:47 am
akro
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Medium
Report
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.